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a b s t r a c t
Mitochondrial dysfunction is a fundamental abnormality in the vascular endothelium and smooth
muscle of patients with pulmonary arterial hypertension (PAH). Because coenzyme Q (CoQ) is essential
for mitochondrial function and efﬁcient oxygen utilization as the electron carrier in the inner
mitochondrial membrane, we hypothesized that CoQ would improve mitochondrial function and beneﬁt
PAH patients. To test this, oxidized and reduced levels of CoQ, cardiac function by echocardiogram,
mitochondrial functions of heme synthesis and cellular metabolism were evaluated in PAH patients
(N¼8) in comparison to healthy controls (N¼7), at baseline and after 12 weeks oral CoQ supplementa-
tion. CoQ levels were similar among PAH and control individuals, and increased in all subjects with CoQ
supplementation. PAH patients had higher CoQ levels than controls with supplementation, and a
tendency to a higher reduced-to-oxidized CoQ ratio. Cardiac parameters improved with CoQ supple-
mentation, although 6-minute walk distances and BNP levels did not signiﬁcantly change. Consistent
with improved mitochondrial synthetic function, hemoglobin increased and red cell distribution width
(RDW) decreased in PAH patients with CoQ, while hemoglobin declined slightly and RDW did not change
in healthy controls. In contrast, metabolic and redox parameters, including lactate, pyruvate and reduced
or oxidized gluthathione, did not change in PAH patients with CoQ. In summary, CoQ improved
hemoglobin and red cell maturation in PAH, but longer studies and/or higher doses with a randomized
placebo-controlled controlled design are necessary to evaluate the clinical beneﬁt of this simple
nutritional supplement.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Pulmonary arterial hypertension (PAH) is a fatal disease char-
acterized by a proliferative panvasculopathy that leads to right-
sided heart failure. Abnormalities of mitochondrial function
are mechanistically associated with the pulmonary vascular
and cardiac disease [1–4]. Mitochondria are the principal source
of energy for all cells through oxidative phosphorylation, and
the main site for heme synthesis. Iron is incorporated into the
protoporphyrin ring by mitochondrial ferrochelatase to produce
heme and ultimately hemoproteins, such as hemoglobin. Abnorm-
alities of mitochondrial oxygen utilization, energy production, and
heme synthesis are all well described in PAH patients and have
been linked to the underlying pathophysiology contributing to the
disease [2,3,5–7]. Consistent with abnormalities of heme synthesis
and hemoglobin production, PAH patients have greater variation in
the size distribution of red blood cells, i.e. an increase in the red
cell distribution width (RDW). In fact, studies show that RDW is a
prognostic marker of pulmonary artery pressures, heart failure
and mortality in PAH patients [8,9], and is independent of
the B-type natriuretic protein (BNP), a validated biomarker of
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myocardial stress [8]. In addition to synthetic and energetic
functions, mitochondria are also a primary site for production of
reactive oxygen species, as a byproduct of the electron transport
reactions, which contribute to injury and inﬂammation of the
pulmonary vasculature in PAH [10]. Taken together, the evidence
suggests that interventions aimed at improvement of mitochon-
drial function might beneﬁt PAH.
Coenzyme Q (CoQ) is one of the most widely used cofactors for
treating mitochondrial-related diseases. CoQ has an important role
in mitochondrial metabolism by functioning as the electron carrier
in the inner mitochondrial membrane, transferring electrons from
complexes I and II to complex III [11], but CoQ also acts as an
antioxidant via a redox cycle. During electron transport, Q is
reduced to the ubiquinol (QH2) form as it picks up electrons and
protons, and is oxidized to the ubiquinone (Q) as it releases
electrons and protons. In contrast to other redox cycling antiox-
idants, CoQ inhibits both the initiation and the propagation of lipid
and protein oxidation. Multiple studies have shown that CoQ is
beneﬁcial in prevention and treatment of cardiovascular diseases,
including hypertension, angina and heart failure [12–14]. In this
context, we hypothesized that CoQ supplementation in patients
with PAH would improve mitochondrial energetic and synthetic
functions, and potentially beneﬁt patients. To test this hypothesis,
we evaluated blood levels of reduced and oxidized CoQ, hemoglo-
bin and RDW, metabolic parameters of redox status including
reduced and oxidized glutathione and pyruvate and lactate, in PAH
patients in comparison to healthy controls at baseline and follow-
ing 12 weeks of oral CoQ supplementation.
Materials and methods
Study population
Healthy individuals and patients diagnosed with Class I PAH
according to the revised clinical classiﬁcation of pulmonary
hypertension [15] between the ages of 18 and 60 were enrolled.
All subjects enrolled with PAH were on stable medications and a
diagnostic right heart catheterization had previously conﬁrmed
diagnosis. Exclusion criteria included: participation in other
studies, hepatic insufﬁciency (transaminase levels levels 44 fold
the upper limit of normal, bilirubin 42 fold the upper limit for
normal), renal insufﬁciency (creatinine level 42.0mg per decili-
ter), pregnancy, breastfeeding or lack of use of safe contraception,
acute heart failure episode within the last 3 months, known
allergy to any of the study drugs, history of drug or alcohol abuse
within the last 12 months. All patients provided written informed
consent under an Institutional Review Board approved protocol at
the Cleveland Clinic.
CoQ therapy
Individuals received treatment for 12-weeks with 100mg
capsules of Co-enzyme Q10 (the reduced form, Lot# 07319060
and Lot# 31111, Health Thru Nutrition, Westbury, NY 11590) taken
orally three times a day for a total daily dose of 300mg. This
formulation was chosen because it is both hydrosoluble and
liposoluble. Individuals were evaluated clinically and for research
testing at enrollment to the study (time 0), and at 6 and 12 weeks
after starting the treatment. CoQ tablets were brought to each visit
and counted by investigators in order to monitor adherence to
dosage and ingestion. Furthermore, total and reduced CoQ levels
were measured in blood at each visit by Mayo Medical laboratories
using high performance liquid chromatography with electro-
chemical detection [16].
Clinical assessment of PAH: pulmonary vascular and cardiac function
Each PAH patient was classiﬁed by the New York Heart
Association functional status (I IV) based on symptoms and
severity. Functional status was also assessed by a standard 6 min-
ute walk which was performed in accordance with the American
Thoracic Society Recommended guidelines, which included assess-
ment of dyspnea and fatigue by the Borg Dyspnea and Fatigue
Scale [17] B-type natriuretic peptide (BNP) at each visit provided
quantitative assessment of acute heart failure.
Echocardiograms were performed at baseline and week 12 for
all PAH patients as previously described [18,19]. Two dimensional
echocardiogram and Doppler exams were performed by a single
experienced sonographer, on a General Electric Healthcare Vivid
E9 4D Imaging System, Wauwatosa, WI. Interventricular septal
(IVSD) thickness in end-diastole, left ventricular end-diastolic
dimension (LVEDD), left ventricular end-systolic dimension
(LVESD) and posterior wall thickness (PWD) in diastole were
measured from the 2D parasternal long axis image following
American Society of Echocardiography (ASE) guidelines [18,19].
Left ventricular (LV) mass was determined from 2D measurements
using the formula: LV Mass¼1.04(IVSþPWþLVEDD)3–LVEDD3)–
13.6g (Devereaux Regression) LV ejection fraction was determined
by visual assessment, and/or apical biplane volumes. LV end-
diastolic and end-systolic volumes were calculated from the apical
4 and 2 chamber views using the modiﬁed Simpson method. LV
fractional shortening was determined from parasternal 2D analysis
(LVEDD–LVESD/LVEDD100). Right ventricular (RV) end-diastolic
and end-systolic areas were measured in the apical 4-chamber
view by tracing the endocardial border of the RV and the tricuspid
annular plane. RV fractional area change was calculated as follows:
RV end-diastolic area minus RV end-systolic area divided by RV
end-diastolic area100. Right atrial volume was measured in the
apical 4-chamber view by using the single-plane area–length
method. The peak pulmonary artery systolic pressure (PASP) was
estimated from the systolic pressure gradient between the RV and
the right atrium by the peak continuous-wave Doppler velocity of
the TR jet using the modiﬁed Bernoulli equation plus estimated
right atrial pressure (RAP). RAP was estimated from the subcostal
window approach measuring changes in inferior vena caval
size and collapsibility as determined by the respiratory sniff
test following ASE guidelines. Echo-Doppler was used to estimate
pulmonary vascular resistance (PVR). The highest Doppler
Table 1
Baseline characteristics of study population.
Variable Healthy,
N ¼ 7
PAH,
N¼8
P-value
Age (years) 4275 4173 0.8
Race (Caucasian/African American/Asian) 6/0/1 7/1/0 0.2
Gender (female/male) 6/1 7/1 0.9
Height (cm) 17877 16774 0.3
Weight (kg) 6275 8278 0.04
Pulse (beats/min) 6473 8176 0.02
O2 saturation (% of hemoglobin) 99.370.3 97.670.5 0.02
RVSP (mmHg)a  6777 
6 minute walk distance (M)  490728 
BNP (pg/ml)b  57734 
Fick Cardiac Index (l/min)a  2.570.3 
Mean pulmonary arterial pressure (mmHg)a  4975
Pulmonary vascular resistancea (wood units)  9.972
NYHA classiﬁcation (I/II/III/IV)  0/7/1/0
a Right heart catheterization done as diagnostic procedure not for research;
RVSP, Right Ventricular Systolic Pressure.
b BNP, B-type Natriuretic Peptide.
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continuous wave tricuspid valve peak velocity jet obtained from
multiple views (parasternal long axis, parasternal short axis, apical
4-chamber, subcostal or apical off-axis imaging) was determined
as the maximum tricuspid regurgitant velocity (TRV). Pulsed wave
Doppler sample was placed in the right ventricular outﬂow tract
(RVOT) at the level of the aortic valve in the parasternal short axis
view just below the pulmonic valve so that pulmonic valve closure
is identiﬁed. The Doppler spectrum was traced to determine the
time velocity integral of the RVOT. PVR was estimated by: PVR
(Wood units)¼TRVMAX (m/s)/RVOTTVI (cm)10þ0.16. Tricuspid
annular plane systolic excursion was obtained from the apical
4 chamber RV focused view with M-mode echocardiography
across the TV annulus, measuring the distance of longitudinal
annular movement from end diastole to end systole towards the
apex. Pulsed Doppler cardiac time intervals of right ventricular
ejection time (RVET) and Tricuspid valve opening to closure were
used to calculate RV myocardial performance or TEI Index values.
With the exception of the TR continuous wave maximum velocity
all echo parameters were measured in triplicate and reported as
an average value.
Metabolic effects of CoQ
To assess CoQ effects on intracellular metabolism and redox status,
plasma levels of lactate and pyruvate, reduced and oxidized glu-
tathione (GSH, GSSG, respectively), and the reduced (CoQ10H2) and
oxidized (CoQ) forms of CoQ were determined at each visit. Plasma
lactate and pyruvate measurements were performed in diluted
samples using the Lactate Assay K607-100 and Pyruvate Assay
K609-100, respectively (BioVision, Inc., Milpitas, CA). A range of
authentic lactate (0–0.25mM) and pyruvate (0–0.1mM) standards
were used in the assay. Reduced and oxidized glutathione were
measured in serum [20]. In brief, total glutathione levels were
determined by mixing equal amounts of serum with 10mM 5,50-
dithiobis-2-nitrobenzoic acid (DTNB) in 100mM potassium phos-
phate, pH 7.5, which contained 17.5 mM EDTA. An aliquot (50 ml) of the
solution was added to a cuvette containing 0.5U of glutathione
disulﬁde reductase (Sigma type III, Sigma Chemical, St. Louis, MO)
in 100mM potassium phosphate and 5mM EDTA, pH 7.5. After 1min,
the reaction was initiated with 220nmol of NADPH in a ﬁnal reaction
volume of 1ml. The rate of reduction of DTNB was recorded
continuously at 412nm by a spectrophotometer with a Kinetics/Time
feature (Beckman DU-640, Beckman Instruments, Inc., Fullerton, CA).
In order to assay GSSG, equal volumes of serum and N-
ethylmaleimide (NEM) were added to serum. An aliquot (50 ml) of
the solution was passed at one drop/sec through a C15 Sep-Pak
cartridge (Walters Associates, Framingham, MA) that had been
washed with methanol followed by water. The cartridge was then
washed with 1ml of 100mM potassium phosphate and 5mM EDTA,
pH 7.5. A 750 ml aliquot of the eluate was added to a cuvette with 250
nmol of DTNB and 0.5U of GSSG reductase. The assay then proceeded
as in the measurement of total GSH. The levels of GSH and GSSG were
based on standard curves.
Hematologic effects of CoQ: heme synthesis and hematopoiesis
To assess heme synthetic effects of CoQ, blood samples
were obtained for measures of complete blood cell count, red
Fig. 1. CoQ supplementation increases serum levels of the oxidized ubiquinone (CoQ10)
and the reduced ubiquinol (CoQ10H2). PAH patients have greater increase in CoQ than
controls at 12 weeks. ⋆ indicates Po0.05 comparison of PAH to healthy control at the
indicated time. The brackets at the top and bottom of each panel show P values for the
ANOVA/post-hoc Tukey test within PAH or control groups, respectively.
Table 2
CoQ levels in PAH patients and Healthy Controls.
Variable PAH Controls
Baseline 6 weeks 12 weeks P-value Baseline 6 weeks 12 weeks P-value
Total CoQ (mg/L) 0.89718 3.97 .6 4.67 .5 o0.001 0.737 .03 2.47 .4 2.070.3n o0.001
Reduced CoQ (mg/L) 0.847 .16 3.77 .6 4.47 .5 o0.001 0.697 .03 2.37 .4 1.970.3n o0.001
n P r 0.05 PAH compared to controls for the corresponding time point in the study.
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cell distribution width (RDW), and erythropoietin (epo). epo
was measured in plasma using quantikine ELISA (R&D system,
MN) [21].
Statistical analysis
Data are reported in aggregate as mean7SEM for continuous
data and as n (%) for categorical data. Statistical changes from
Fig. 2. Cardiac function improves in PAH patients receiving CoQ. Boxes show the
median and 25% and 75%. Paired samples from baseline to 12 weeks of CoQ are
connected by lines.
Fig. 3. Hemoglobin and mean corpuscular hemoglobin increase, and RDW decreases
in PAH patients supplemented with CoQ. Healthy controls have a tendency to
decrease hemoglobin, and do not show changes in RDW. ⋆ indicates Po0.05
comparison of PAH to healthy controls at the indicated time.
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baseline were assessed using a paired t-test. Spearman correlation
coefﬁcients were used to detect associations between parameters
including all visits. Signiﬁcance was set at an alpha of 0.05. Data
were analyzed using the JMP 9 statistical software (SAS Institute,
Cary, NC). For Figs. 1, 4 and 5 the data are reported as mean7SEM.
ANOVAwas used to analyze the data within PAH or control groups.
The Tukey test was used when differences were detected by
ANOVA. If the data were not normally distributed, a log transform
was used for statistical analysis only. Comparisons between PAH
and healthy controls at each time point were carried out using
t-test.
Results
Study population
Ten patients with PAH (9 idiopathic and 1 heritable) and
8 healthy controls were enrolled. Two PAH patients dropped out
of the study. One after 1 week in the study due to unremitting
headache, and another after 6 weeks of CoQ due to hyperkalemia.
One healthy control dropped out after 1 week of CoQ due to
nausea. PAH patients were similar to healthy subjects in terms of
age, gender, race and height, but tended to have greater body
mass, and higher resting heart rate and lower oxygen satura-
tion (Table 1). All PAH subjects had no change in their PAH therapy
during the study. Two PAH subjects were on a short course of
antibiotics between visit 2 and 3 and one PAH subject had a 5 day
course of prednisone for a gout ﬂare. All subjects maintained the
same level of activity during the course of the study.
CoQ levels increase in healthy controls and PAH patients with
supplementation
PAH and controls had equivalent endogenous total and reduced
CoQ levels (P¼0.4). Following supplementation, for PAH patients,
total and reduced CoQ increased 4-fold at week 6, and 5-fold
at week 12. In controls, total and reduced CoQ also increased, but
only by 3-fold at 6 and 12 weeks. Thus, the total, reduced and
oxidized CoQ levels were higher in PAH patients than controls at
week 12 (Fig. 1 and Table 2). The reduced-to-oxidized CoQ ratio
tended to be higher in PAH as compared to control, but did not
reach signiﬁcance (P¼0.1).
CoQ effects on clinical parameters
Although the primary aim of the study was to determine effects
of CoQ on mitochondrial functions, clinical evaluations were
performed to detect any potential beneﬁts and/or adverse effects.
The 6-minute walk distances and BNP levels did not signiﬁcantly
change with CoQ supplementation (all P40.1). The Borg Dyspnea
and Fatigue scores were similar before and after CoQ supplemen-
tation (all P40.4). However, the Borg Dyspnea and Fatigue scores
were directly correlated to CoQ levels prior to supplementation
(Dyspnea and CoQ, R2¼0.59, P¼0.026; Fatigue and CoQ, R2¼0.92,
P¼0.0005) and the relationships were lost when patients were
receiving CoQ (all P40.3). Echocardiographic parameters
improved over the course of the study (Fig. 2). The left ventricular
end diastolic volume (LVEDV) decreased signiﬁcantly [LVEDV (ml):
baseline 81710, 12 weeks CoQ 7078; P¼0.04]. The right ven-
tricular outﬂow (velocity time interval) improved [baseline
11.371.4 cm, 12 weeks CoQ 13.571.6 cm; P¼0.04], and RV
myocardial performance (Tei index) tended to improve [RV Tei
index: baseline 0.970.2, 12 weeks CoQ 0.770.1; P¼0.09] (Fig. 2).
In addition, the right atrial pressure (RAP) decreased with CoQ and
tricuspid regurgitation (TR) decreased [RAP (mmHg): baseline
1072, 12 weeks CoQ 871; P¼0.03 and TR grade: baseline
1.470.3, 12 weeks CoQ 1.270.3; P¼0.03] (Fig. 2). There were
no signiﬁcant correlations between echocardiographic parameters
and CoQ (all P40.1).
CoQ effects on heme synthesis in PAH and controls
Hemoglobin (Hgb) and mean corpuscular Hgb (MCH) increased
in PAH patients, but the red blood cell count and hematocrit
remained unchanged (Fig. 3 and Table 3). In parallel, the RDW
decreased in PAH patients with CoQ (Table 3). Hemoglobin and
MCH were unrelated to total CoQ, but were directly related to the
reduced-to-oxidized CoQ ratio at baseline (Hgb relation to QH2/Q,
R2¼0.57, P¼0.02; MCH relation to QH2/Q, R2¼0.54, P¼0.03) and
tended to be directly related after 12 weeks of CoQ supplementa-
tion (Hgb relation to QH2/Q, R2¼0.27, P¼0.18; MCH relation to
QH2/Q, R2¼0.45, P¼0.06). These data indicate that hemoglobin
synthesis at baseline is limited by CoQ, even though levels are in
the normal range. In contrast to PAH patients, but similar to prior
reports, red blood cell numbers and hematocrit decreased slightly,
and mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin content and RDW did not change
in healthy controls on CoQ (all P40.1) (Table 3). Erythropoietin
(Epo) levels in patients with PAH are higher than in healthy
controls [21]. Here, Epo levels were measured to assess other
possible mechanisms of CoQ effect on hemoglobin production. Epo
levels in PAH patients at baseline were similar to levels with CoQ
supplementation [Epo (mIU/ml): baseline 20.875.4, 6 weeks
18.374.5, 12 weeks 19.572.8; P¼0.8].
Effects of CoQ on mitochondria metabolic function
Serum lactate and pyruvate levels were measured as biomar-
kers of mitochondrial-metabolism. Over time of CoQ supplemen-
tation, lactate did not change within control group, but PAH
patients had signiﬁcantly higher lactate than controls by week
Table 3
Hematologic effects of CoQ in PAH and healthy controls.
Variable PAH Controls
Baseline 6 weeks 12 weeks P-value Baseline 6 weeks 12 weeks P-value
Red blood cell (m/ml) 5.270.2n 5.1 7 0.2n 5.2 7 0.2n 0.2 4.570.1 4.270.1 4.370.2 0.02
Hematocrit (%) 43.072.1 42.4 72.1n 43.8 7 1.8n 0.2 39.971.0 37.970.7 38.671.3 0.02
Hemoglobin (g/dl) 14.170.9 14.070.9 14.6 7 0.8 0.01 13.370.4 12.770.3 12.970.5 0.07
Mean corpuscular volume (ﬂ) 82.172.4 83.072.2 83.5 7 2.0 0.06 89.771.3 90.071.0 88.971.3 0.3
Mean corpuscular hemoglobin (pg) 26.871.1 27.370.9 27.8 7 1.0 0.006 29.970.8 30.270.5 29.970.7 0.5
Mean corpuscular hemoglobin content (g/dl) 32.670.6 33.070.4 33.2 7 0.7n 0.06 33.370.5 33.670.3 33.570.4 0.6
Red blood cell distribution width (%) 15.070.6n 15.170.7n 14.5 7 0.5n 0.04 12.970.2 12.970.2 12.970.4 1.0
n Pr0.05 PAH compared to controls for the corresponding time point in the study.
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12 (Fig. 4). Pyruvate levels changed over time in controls (P¼0.04),
but there was no detectable change in pyruvate levels in PAH
patients over time of CoQ supplementation (Fig. 4). The net effect
was that total lactateþpyruvate levels were higher in PAH than
control patients at 12 weeks. The lactate/pyruvate ratios did not
change with CoQ supplementation in the PAH or control groups,
and there were no detectable differences between the groups at
any time (Fig. 4). Lactate and pyruvate levels were not correlated
with CoQ (all P40.1).
Reduced (GSH) and oxidized (GSSG) glutathione were mea-
sured as another redox status indicator. GSSG levels did not
change signiﬁcantly in PAH patients or controls (all P40.8).
Reduced (GSH) and total (GSHþGSSG) levels were signiﬁcantly
lower in PAH patients as compared to Controls at the 6 week time
point. However, PAH patients and Controls had statistically indis-
tinguishable GSH and total GSHþGSSG by week 12 of CoQ
supplementation. The GSH/GSSG ratio did not change signiﬁcantly
over time of CoQ supplementation for PAH or control subjects, and
there was no statistically detectable difference in the ratios
between PAH and control individuals at any time point (Fig. 5).
Discussion
CoQ is essential to key mitochondria functions. Oxidative
phosphorylation by the mitochondria requires CoQ. Complex I
and complex II in the inner mitochondrial membrane transfer
Fig. 4. Lactate and pyruvate do not change with CoQ supplementation within PAH
or healthy control groups with CoQ. The lactate levels for PAH patients at 12 weeks
is signiﬁcantly higher than controls. ⋆ indicates Po0.05 comparison of PAH to
healthy control at the indicated time. The brackets at the top and bottom of each
panel show P values for ANOVA/Tukey’ post-hoc test within PAH or control groups,
respectively.
Fig. 5. Reduced GSH and GSSG do not change with CoQ supplementation in PAH or
healthy controls. ⋆ indicates Po0.05 comparison of PAH to healthy control at the
indicated time. The brackets at the top and bottom of each panel show P values for
ANOVA within PAH or control groups, respectively.
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electrons to CoQ, which subsequently transfers the electrons to
Complex III. CoQ also provides antioxidant function, redox cycling
from the reduced ubiquinol (QH2) to the oxidized ubiquinone
(Q) as it transfers electrons in the mitochondria. Furthermore, CoQ
is an obligate cofactor for mitochondria uncoupling, which reduces
the electrochemical gradient, and lowers the capacity to produce
ATP as well as reactive oxygen species [23]. Increased mitochon-
dria production of reactive oxygen species are well-described in
PAH and contribute to the vascular remodeling [24,25]. Thus, CoQ
supplementation theoretically might improve cellular metabolism
and minimize oxidative damage. To our knowledge, this is the ﬁrst
study to investigate CoQ effects on mitochondrial dysfunction in
patients with PAH. Similar to prior reports of positive effects of
CoQ on myocardial metabolism and function in left heart failure
[2,12], CoQ improved the right and left heart function in PAH
patients in this study. However, the greatest effect of CoQ occurred
in the nonmetabolic mitochondrial function of heme synthesis in
the 12 week period of the study.
Pulmonary hypertension in avian species, rodent species, lambs
and humans is characterized by deﬁciencies in mitochondrial
functions [2,22,24–29]. For example, endothelial cells in the
human PAH lung have mitochondrial respiration abnormalities,
and have greater reliance on glycolysis [2]. Consistent with this
ﬁnding, lungs and hearts of patients with PAH have greater uptake
of the glucose analog tracer [18F] ﬂuoro-deoxy-D-glucose (FDG) by
positron emission tomography (PET) [2,30]. Dichloroacetate (DCA),
which inhibits pyruvate dehydrogenase kinase (the enzyme that
selectively blocks pyruvate dehydrogenase and the entry of
pyruvate in the Tricarboxylic Acid cycle), reverses pulmonary
hypertension of Fawn Hooded rats [26]. Here, measures of serum
pyruvate, lactate and glutathione did not change in PAH or control
subjects over time of the study. This may be due to the dose of
the CoQ or the 12 week duration of the supplementation, either
of which may be inadequate to see effects in serum levels of
metabolic indices.
Many studies have identiﬁed abnormalities in iron metabolism
and hematologic abnormalities in PAH [6–9,22]. Consistent with
the concept of defective heme production, PAH patients here, and
in past studies, have greater variation in the size distribution of the
red cell distribution width (RDW), which directly correlates to
pulmonary artery pressures and inversely to 6-minute walk
distances [6–9]. Unfortunately, iron levels, transferrin, or B12
levels which impact hemoglobin synthesis, were not available for
participants in the study, and this is a limitation for the study.
However, in this study, hemoglobin and mean corpuscular hemo-
globin increased in the PAH patients, identifying a role for CoQ
in heme production and red blood cell maturation. Although,
standard clinical biomarkers, such as the 6-minute walk distance
and BNP did not improve, echocardiographic measures of right
and left heart function improvements provided promise that
improvements may have occurred if CoQ therapy were continued
for a longer time. In fact, ﬁndings of unchanged exercise capacity
with short-term CoQ supplementation in heart failure have been
documented in prior studies [14]. In a randomized control study of
CoQ (300mg daily) in 420 patients with NYHA class 3 or 4 heart
failure [23], BNP tended to decrease after 3 months of CoQ.
However, striking clinical outcomes were seen after 2 years of
CoQ, e.g. improvement in NYHA class, 50% reduction in major
adverse cardiovascular events including death, and 50% drop in all
cause mortality. CoQ levels have been shown, in fact, to be an
independent predictor of mortality in patients with congestive
heart failure; the lower the plasma CoQ levels, the greater the
risk of mortality from congestive heart failure. The association
between increased mortality in CHF and lower CoQ levels is
stronger than the association observed between CHF mortality
and the well-established NT-proBNP [31]. Although CoQ levels are
higher in the heart than in other organs in the body, CoQ levels are
deﬁcient in myocardium of patients with congestive left-sided
heart failure [32]. In this context, although PAH and controls had
similar endogenous CoQ levels at baseline, supplementation led to
greater increase of CoQ levels in PAH patients as compared to
healthy controls. Adherence may have been better in the PAH
group, but more likely the results indicate that metabolism of CoQ
is altered in the patients [14].
This mechanistic study of CoQ effects in PAH did not aim to test
clinical improvement. Standard clinical markers of 6-minute walk
and BNP did not change over the 12 weeks of the study. However,
the decrease in RDW and improvements in echocardiographic
parameters at 12 weeks suggest that trials of longer duration, and/
or higher dose of CoQ, may demonstrate beneﬁt. Equally impor-
tant, although this was a small cohort, CoQ was well tolerated,
conﬁrming minimal side effects of supplementation [32].
Altogether, the known relationship of CoQ to outcomes in left-
sided heart failure patients, and the ﬁnding that CoQ supplemen-
tation improves heme synthetic and cardiac functions in PAH,
provide rationale for studies of longer duration to evaluate clinical
beneﬁts over time.
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